NCT00569335已完成2 期
Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- Safety
研究概览
简要总结
Phase II trial of combination therapy with S-1, irinotecan, and bevacizumab (SIRB) in patients with unresectable or recurrent colorectal cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed colorectal carcinoma with inoperable, locally advanced, or metastatic disease, not amenable to curative therapy
- •Measurable disease or non-measurable but assessable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)
- •Patients with no previous treatment (radiotherapy or chemotherapy). Patients who have received postoperative adjuvant chemotherapy are eligible if relapse is diagnosed more than 180 days after the end of such treatment.
- •Preoperative or postoperative irradiation (<30 Gy) for rectal cancer is possible
- •Age >20 years
- •Life expectancy of at least 3 months
- •ECOG PS of 0 or 1
- •Adequate function of major organs as defined below:
- •Hemoglobin >9.0 g/dL
- •White blood cell count >3,000/mm3
- •Neutrophil count >1,500/mm3
- •Platelet count >100,000/mm3
- •Total bilirubin <1.5 mg/dL
- •AST and ALT <100 U/L (<200 U/L in patients with liver metastasis)
- •Serum creatinine <1.2 mg/dL
- •Creatinine clearance estimate by the Cockcroft-Gault method >50 mL/min (reduce initial dosage by one step if ≥50 but <80 mL/min)
- •Able to take capsules orally.
- •No electrocardiographic abnormalities within 28 days before enrollment that would clinically preclude the execution of the study, as judged by the investigator.
- •Voluntary written informed consent.
排除标准
- •Serious drug hypersensitivity or a history of drug allergy
- •Active double cancer
- •Active infections (e.g., patients with pyrexia of 38℃ or higher)
- •History of gastrointestinal perforation, intestinal tract paralysis, or ileus within 1 year.
- •Uncontrolled hypertension
- •Serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart failure, renal failure, hepatic failure, or poorly controlled diabetes)
- •Moderate or severe ascites or pleural effusion requiring treatment
- •Watery diarrhea
- •Treatment with flucytosine or atazanavir sulfate
- •Metastasis to the CNS
- •Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing mothers. Men who are currently attempting to conceive children.
- •Severe mental disorder
- •Continuous treatment with steroids
- •Urine dipstick for proteinuria should be <2+
- •Patient with a past history of thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism
- •Major surgical procedure, open biopsy, or clinically significant traumatic injury within 4 weeks
- •Long-term daily treatment with aspirin (>325 mg/day)
- •History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
- •Judged ineligible for participation in the study by the investigator for safety reasons.
研究组 & 干预措施
1
Experimental
S-1, Irinotecan, Bevacizumab
干预措施: S-1, Irinotecan, Bevacizumab (Drug)
结局指标
主要结局
Safety
时间窗: any time
次要结局
- Progression-free survival, Response rate, Overall survival, Time to treatment failure, Treatment situation(every course for first three courses, then every other course)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
1 期
Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal CancerMetastatic Colorectal CancerNCT03380689Fujian Cancer Hospital
已完成
2 期
Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal CancerColorectal CancerNCT00569790Taiho Pharmaceutical Co., Ltd.53
招募中
2 期
Study of Bevacizumab + Irinotecan + S-1 therapy in metastatic colorectal cancer with KRAS mutant typeJPRN-UMIN000004630Tsuchiura kyodo general hospital25
Unknown
2 期
S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric CancerGastric CancerNCT00343668Korean Cancer Study Group44
已完成
2 期
A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric CancerStomach NeoplasmsNCT00512681National Cancer Center, Korea44